Effect of Sacubitril/Valsartan on Natriuresis, Diuresis and Blood Pressure in Hypertensive Patients

Кобалава, Ж. Д.; Villevalde, S.; Meray, I.; Lukina, O.

doi:10.20996/1819-6446-2017-13-3-370-377

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kobalava et al 26 performed an objective evaluation of natriuresis by measuring fractional sodium excretion and urinary cyclic guanosine monophosphate in hypertensive patients and compared it between valsartan and LCZ696. This study showed more effective natriuresis in patients on LCZ696 with a resultant reduced SBP and DBP.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Sacubitril/Valsartan in Hypertension

Malik¹,

Aronow²

2022

American Journal of Therapeutics

View full text Add to dashboard Cite

Background: Sacubitril/valsartan (LCZ696) has progressed to be one of the most promising medication since its approval for chronic heart failure with reduced ejection fraction. Recent data have suggested a superior blood pressure control with LCZ696.Study Question: What is the antihypertensive efficacy and safety profile of sacubitril/valsartan? Data Sources: Randomized controlled trials (RCTs) comparing the efficacy and safety of LCZ696 against a placebo or angiotensin receptor blocker (ARB). RCTs were identified from a comprehensive search in PubMed, Embase, Cochrane library, and clinicaltrials.gov. Study Design:We used a change in systolic and diastolic blood pressures, both sitting as well as ambulatory, to calculate relevant effect sizes with their standard errors from the available change in mean and SD data. In addition, we also collected categorical data for the reported adverse effects from these trials. We performed a series of pairwise meta-analyses between LCZ696 versus an active comparator or a placebo.Results: Eleven RCTs with a total of 6028 participants had the relevant data available. Our meta-analysis showed that LCZ696 is an effective and a safe treatment for hypertension. It outperformed ARBs in every category, and the results are consistent across the different dosages of LCZ696. Compared with ARBs, 200 mg of LCZ696 reduced systolic blood pressure and diastolic blood pressure (DBP) by 4.62 mm Hg (95% confidence interval, 3.33-5.90, P , 0.001) and 2.13 mm Hg (95% confidence interval, 1.69-2.57, P , 0.001), respectively. Similarly, 400 mg of LCZ696 reduced systolic blood pressure and diastolic blood pressure by 5.50 mm Hg (2.94-8.07, P , 0.001) and 2.51 mm Hg (1.80-3.21, P , 0.001), respectively, in comparison with ARBs. The adverse effects with LCZ696 were not significantly higher compared with ARBs or placebo.Conclusions: Sacubitril/valsartan is more effective for the management of hypertensive patients, compared with an ARB. Long-term prospective studies are required to identify whether this result translates into morbidity and mortality benefits.

show abstract

Section: Discussionmentioning

confidence: 99%